Bone Morphogenetic Protein Comprehensive Study by Type (Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2, Recombinant Human Bone Morphogenetic Protein (rhBMP) -7), Application (Spinal Fusion, Trauma, Reconstruction, Oral Maxillofacial) Players and Region - Global Market Outlook to 2026

Bone Morphogenetic Protein Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 2.5%  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Bone Morphogenetic Protein Market?

Growth in the number of spinal surgeries and the ease of surgery with the help of BMP, its application is growing quickly in spinal fusion surgery will help to boost global bone morphogenetic protein market in the forecasted market period. Bone morphogenetic protein (BMPs) is the group of growth factors that belong to beta super family (TGF beta). These proteins are naturally occurring proteins. The family of this protein is involved in many cellular responses. Some bone morphogenetic protein are said to induce the formation of bones and cartilage that is they are osteoinductive.

The market study is being classified by Type (Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2 and Recombinant Human Bone Morphogenetic Protein (rhBMP) -7), by Application (Spinal Fusion, Trauma, Reconstruction and Oral Maxillofacial) and major geographies with country level break-up. According to AMA, the Global Bone Morphogenetic Protein market is expected to see growth rate of 2.5%

DePuy Synthes (United States), Ember therapeutics Inc. (United States), Integra Lifesciences Holdings Corporation (United States), Medtronic PLC (Ireland), R&D Systems (United States), Sigma Aldrich Corporation (United States), Smith & Nephew, Inc. (United Kingdom), Stryker Corporation (United States), Thermo Fischer Scientific (United States) and Zimmer Biomet Holdings, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Fidia (Italy) and TRB Chemedica (Switzerland).

Leading global players are focusing on strategic partnerships to improve their products and services. In addition, companies are focusing on increasing their client base to strengthen market position and to enhance product & service offerings. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Bone Morphogenetic Protein market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Bone Morphogenetic Protein market by Type, Application and Region.

On the basis of geography, the market of Bone Morphogenetic Protein has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2020. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Occurrences of Sports-Related Injury
  • Growing Demand for Minimally Invasive Surgeries

Market Trend
  • Upsurge in Medical Tourism in Emerging Countries
  • Technological Advancements in Bone Morphogenetic

Restraints
  • High Cost of Procedure

Opportunities
  • Rising Awareness among the People about Bone Morphogenetic Protein
  • Increase in Healthcare Spending Capacity

Challenges
  • Alternative Treatment Availability





Key Target Audience
Government Research Organization, Private Research Organization, Government Regulatory Bodies, Industry Association, Downstream Vendors and Others

Report Objectives / Segmentation Covered

By Type
  • Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2
  • Recombinant Human Bone Morphogenetic Protein (rhBMP) -7
By Application
  • Spinal Fusion
  • Trauma
  • Reconstruction
  • Oral Maxillofacial
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Occurrences of Sports-Related Injury
      • 3.2.2. Growing Demand for Minimally Invasive Surgeries
    • 3.3. Market Challenges
      • 3.3.1. Alternative Treatment Availability
    • 3.4. Market Trends
      • 3.4.1. Upsurge in Medical Tourism in Emerging Countries
      • 3.4.2. Technological Advancements in Bone Morphogenetic
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bone Morphogenetic Protein, by Type, Application and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Bone Morphogenetic Protein (Value)
      • 5.2.1. Global Bone Morphogenetic Protein by: Type (Value)
        • 5.2.1.1. Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2
        • 5.2.1.2. Recombinant Human Bone Morphogenetic Protein (rhBMP) -7
      • 5.2.2. Global Bone Morphogenetic Protein by: Application (Value)
        • 5.2.2.1. Spinal Fusion
        • 5.2.2.2. Trauma
        • 5.2.2.3. Reconstruction
        • 5.2.2.4. Oral Maxillofacial
      • 5.2.3. Global Bone Morphogenetic Protein Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Bone Morphogenetic Protein: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. DePuy Synthes (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Ember therapeutics Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Integra Lifesciences Holdings Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Medtronic PLC (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. R&D Systems (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sigma Aldrich Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Smith & Nephew, Inc. (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Stryker Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Thermo Fischer Scientific (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Zimmer Biomet Holdings, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Bone Morphogenetic Protein Sale, by Type, Application and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Bone Morphogenetic Protein (Value)
      • 7.2.1. Global Bone Morphogenetic Protein by: Type (Value)
        • 7.2.1.1. Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2
        • 7.2.1.2. Recombinant Human Bone Morphogenetic Protein (rhBMP) -7
      • 7.2.2. Global Bone Morphogenetic Protein by: Application (Value)
        • 7.2.2.1. Spinal Fusion
        • 7.2.2.2. Trauma
        • 7.2.2.3. Reconstruction
        • 7.2.2.4. Oral Maxillofacial
      • 7.2.3. Global Bone Morphogenetic Protein Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bone Morphogenetic Protein: by Type(USD Million)
  • Table 2. Bone Morphogenetic Protein Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2 , by Region USD Million (2015-2020)
  • Table 3. Bone Morphogenetic Protein Recombinant Human Bone Morphogenetic Protein (rhBMP) -7 , by Region USD Million (2015-2020)
  • Table 4. Bone Morphogenetic Protein: by Application(USD Million)
  • Table 5. Bone Morphogenetic Protein Spinal Fusion , by Region USD Million (2015-2020)
  • Table 6. Bone Morphogenetic Protein Trauma , by Region USD Million (2015-2020)
  • Table 7. Bone Morphogenetic Protein Reconstruction , by Region USD Million (2015-2020)
  • Table 8. Bone Morphogenetic Protein Oral Maxillofacial , by Region USD Million (2015-2020)
  • Table 9. South America Bone Morphogenetic Protein, by Country USD Million (2015-2020)
  • Table 10. South America Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 11. South America Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 12. Brazil Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 13. Brazil Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 14. Argentina Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 15. Argentina Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 16. Rest of South America Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 17. Rest of South America Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 18. Asia Pacific Bone Morphogenetic Protein, by Country USD Million (2015-2020)
  • Table 19. Asia Pacific Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 20. Asia Pacific Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 21. China Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 22. China Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 23. Japan Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 24. Japan Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 25. India Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 26. India Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 27. South Korea Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 28. South Korea Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 29. Taiwan Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 30. Taiwan Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 31. Australia Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 32. Australia Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 33. Rest of Asia-Pacific Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 34. Rest of Asia-Pacific Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 35. Europe Bone Morphogenetic Protein, by Country USD Million (2015-2020)
  • Table 36. Europe Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 37. Europe Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 38. Germany Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 39. Germany Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 40. France Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 41. France Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 42. Italy Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 43. Italy Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 44. United Kingdom Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 45. United Kingdom Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 46. Netherlands Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 47. Netherlands Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 48. Rest of Europe Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 49. Rest of Europe Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 50. MEA Bone Morphogenetic Protein, by Country USD Million (2015-2020)
  • Table 51. MEA Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 52. MEA Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 53. Middle East Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 54. Middle East Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 55. Africa Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 56. Africa Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 57. North America Bone Morphogenetic Protein, by Country USD Million (2015-2020)
  • Table 58. North America Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 59. North America Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 60. United States Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 61. United States Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 62. Canada Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 63. Canada Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 64. Mexico Bone Morphogenetic Protein, by Type USD Million (2015-2020)
  • Table 65. Mexico Bone Morphogenetic Protein, by Application USD Million (2015-2020)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Bone Morphogenetic Protein: by Type(USD Million)
  • Table 77. Bone Morphogenetic Protein Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2 , by Region USD Million (2021-2026)
  • Table 78. Bone Morphogenetic Protein Recombinant Human Bone Morphogenetic Protein (rhBMP) -7 , by Region USD Million (2021-2026)
  • Table 79. Bone Morphogenetic Protein: by Application(USD Million)
  • Table 80. Bone Morphogenetic Protein Spinal Fusion , by Region USD Million (2021-2026)
  • Table 81. Bone Morphogenetic Protein Trauma , by Region USD Million (2021-2026)
  • Table 82. Bone Morphogenetic Protein Reconstruction , by Region USD Million (2021-2026)
  • Table 83. Bone Morphogenetic Protein Oral Maxillofacial , by Region USD Million (2021-2026)
  • Table 84. South America Bone Morphogenetic Protein, by Country USD Million (2021-2026)
  • Table 85. South America Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 86. South America Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 87. Brazil Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 88. Brazil Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 89. Argentina Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 90. Argentina Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 91. Rest of South America Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 92. Rest of South America Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 93. Asia Pacific Bone Morphogenetic Protein, by Country USD Million (2021-2026)
  • Table 94. Asia Pacific Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 95. Asia Pacific Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 96. China Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 97. China Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 98. Japan Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 99. Japan Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 100. India Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 101. India Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 102. South Korea Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 103. South Korea Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 104. Taiwan Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 105. Taiwan Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 106. Australia Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 107. Australia Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 108. Rest of Asia-Pacific Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 109. Rest of Asia-Pacific Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 110. Europe Bone Morphogenetic Protein, by Country USD Million (2021-2026)
  • Table 111. Europe Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 112. Europe Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 113. Germany Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 114. Germany Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 115. France Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 116. France Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 117. Italy Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 118. Italy Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 119. United Kingdom Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 120. United Kingdom Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 121. Netherlands Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 122. Netherlands Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 123. Rest of Europe Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 124. Rest of Europe Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 125. MEA Bone Morphogenetic Protein, by Country USD Million (2021-2026)
  • Table 126. MEA Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 127. MEA Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 128. Middle East Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 129. Middle East Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 130. Africa Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 131. Africa Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 132. North America Bone Morphogenetic Protein, by Country USD Million (2021-2026)
  • Table 133. North America Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 134. North America Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 135. United States Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 136. United States Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 137. Canada Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 138. Canada Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 139. Mexico Bone Morphogenetic Protein, by Type USD Million (2021-2026)
  • Table 140. Mexico Bone Morphogenetic Protein, by Application USD Million (2021-2026)
  • Table 141. Research Programs/Design for This Report
  • Table 142. Key Data Information from Secondary Sources
  • Table 143. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bone Morphogenetic Protein: by Type USD Million (2015-2020)
  • Figure 5. Global Bone Morphogenetic Protein: by Application USD Million (2015-2020)
  • Figure 6. South America Bone Morphogenetic Protein Share (%), by Country
  • Figure 7. Asia Pacific Bone Morphogenetic Protein Share (%), by Country
  • Figure 8. Europe Bone Morphogenetic Protein Share (%), by Country
  • Figure 9. MEA Bone Morphogenetic Protein Share (%), by Country
  • Figure 10. North America Bone Morphogenetic Protein Share (%), by Country
  • Figure 11. Global Bone Morphogenetic Protein share by Players 2020 (%)
  • Figure 12. Global Bone Morphogenetic Protein share by Players (Top 3) 2020(%)
  • Figure 13. Global Bone Morphogenetic Protein share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. DePuy Synthes (United States) Revenue, Net Income and Gross profit
  • Figure 16. DePuy Synthes (United States) Revenue: by Geography 2020
  • Figure 17. Ember therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Ember therapeutics Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Integra Lifesciences Holdings Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 20. Integra Lifesciences Holdings Corporation (United States) Revenue: by Geography 2020
  • Figure 21. Medtronic PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 22. Medtronic PLC (Ireland) Revenue: by Geography 2020
  • Figure 23. R&D Systems (United States) Revenue, Net Income and Gross profit
  • Figure 24. R&D Systems (United States) Revenue: by Geography 2020
  • Figure 25. Sigma Aldrich Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 26. Sigma Aldrich Corporation (United States) Revenue: by Geography 2020
  • Figure 27. Smith & Nephew, Inc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. Smith & Nephew, Inc. (United Kingdom) Revenue: by Geography 2020
  • Figure 29. Stryker Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. Stryker Corporation (United States) Revenue: by Geography 2020
  • Figure 31. Thermo Fischer Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 32. Thermo Fischer Scientific (United States) Revenue: by Geography 2020
  • Figure 33. Zimmer Biomet Holdings, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Zimmer Biomet Holdings, Inc. (United States) Revenue: by Geography 2020
  • Figure 35. Global Bone Morphogenetic Protein: by Type USD Million (2021-2026)
  • Figure 36. Global Bone Morphogenetic Protein: by Application USD Million (2021-2026)
  • Figure 37. South America Bone Morphogenetic Protein Share (%), by Country
  • Figure 38. Asia Pacific Bone Morphogenetic Protein Share (%), by Country
  • Figure 39. Europe Bone Morphogenetic Protein Share (%), by Country
  • Figure 40. MEA Bone Morphogenetic Protein Share (%), by Country
  • Figure 41. North America Bone Morphogenetic Protein Share (%), by Country
List of companies from research coverage that are profiled in the study
  • DePuy Synthes (United States)
  • Ember therapeutics Inc. (United States)
  • Integra Lifesciences Holdings Corporation (United States)
  • Medtronic PLC (Ireland)
  • R&D Systems (United States)
  • Sigma Aldrich Corporation (United States)
  • Smith & Nephew, Inc. (United Kingdom)
  • Stryker Corporation (United States)
  • Thermo Fischer Scientific (United States)
  • Zimmer Biomet Holdings, Inc. (United States)
Additional players considered in the study are as follows:
Fidia (Italy) , TRB Chemedica (Switzerland)
Select User Access Type

Key Highlights of Report


May 2021 242 Pages 97 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increasing Occurrences of Sports-Related Injury " is seen as one of major growth factors of Bone Morphogenetic Protein Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global (United States, European Union and China) Bone Morphogenetic Protein report Report?